CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab.

Int J Environ Res Public Health · 2021 · PMC8346113 · PMID 34360456

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

In PPMS, a significant reduction in the ARR ( p = 0.008), a reduction in active lesions at the six- ( p = 0.0028) and twelve-month follow-ups ( p = 0.0458) and a positive trend for reduction in EDSS was found.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.